# Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia

> **NCT00022971** · PHASE1 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 35 (actual)

## Conditions studied

- Diffuse Large B-Cell Lymphoma
- Follicular Lymphoma
- Chronic Lymphocytic Leukemia
- Mantle Cell Lymphoma
- Small Lymphocytic Lymphoma

## Interventions

- **BIOLOGICAL:** Apolizumab
- **BIOLOGICAL:** Rituximab

## Key facts

- **NCT ID:** NCT00022971
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2001-08-15
- **Primary completion:** 2010-01-22
- **Final completion:** 2017-03-17
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2019-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00022971

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00022971, "Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00022971. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*